The study protocol was approved by the institutional review board of Hokkaido University Hospital, and patient consent was not deemed necessary because data were obtained from medical charts and ...

Lesion (arrow) shows hypointensity on T2-weighted image (A), hyperintensity on high b-value DWI (B), hypointensity on ADC map (C), and focal early enhancement on dynamic contrast-enhanced image (D).

In a cohort of US veterans with prostate cancer who were on active surveillance, negative multiparametric MRI had a 75% negative predictive value for ruling out disease of grade group 2 or higher at ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...

A recent BMJ Oncology study screens the prevalence of prostate magnetic resonance imaging (MRI) lesions in men based on age rather than prostate-specific antigen (PSA) levels. Study: Prevalence of MRI ...

A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate cancer treatment, fuelling the ongoing industry buzz for the promising ...

GSK plc (NYSE:GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical ADC for metastatic castration-resistant prostate ...